ninth international symposium on regional cancer therapies
TRANSCRIPT
For
addi
tion
al in
form
atio
n o
r to
reg
iste
r on
line,
con
tact
:
htt
ps:
//cc
ehs.
up
mc.
com
F e b r u a r y 1 5 – 1 7 , 2 0 1 4
Ninth International Symposium on
Regional Cancer TherapiesSheraton Steamboat Springs
Steamboat Springs, Colorado
Sponsored by
David C. Koch
Regional Cancer Therapy Center
and
University of Pittsburgh School of Medicine
Center for Continuing Education
in the Health Sciences
and
UPMC Cancer Centers
In Collaboration with
The University of Maryland
Marlene and Stewart Greenebaum
Cancer Center
The Medical College of Wisconsin
Cancer Center
Course Co-Directors
H. Richard Alexander, MD
Professor of Surgery
University of Maryland School of Medicine
Baltimore, Maryland
David L. Bartlett, MD
Professor of Surgery
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Robert P. Edwards, MD
Professor, Obstetrics, Gynecology and
Reproductive Sciences
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
T. Clark Gamblin, MD, MS
Associate Professor of Surgery
Medical College of Wisconsin
Milwaukee, Wisconsin
David
C. K
och
Regi
onal
Canc
er T
hera
py C
ente
r
UPM
C Ca
ncer
Pav
ilion,
Sui
te 4
13
5150
Cen
tre A
venu
e
Pitts
burg
h, P
A 15
232
Nonp
rofit
Org
.U.
S. P
osta
gePA
IDPi
ttsbu
rgh,
PA
Perm
it No
. 383
4
Nin
th I
nte
rnat
ion
al S
ympo
siu
m o
n
Reg
ion
al C
ance
r T
hera
pies
Sher
aton
Ste
ambo
at S
prin
gs, S
team
boat
Spr
ings
, Col
orad
o
Fe
br
ua
ry
15
–1
7,
20
14
~ 2 ~ ~ 3 ~
Intent and Overview
This course is designed to cover the most recent advances in cancer therapy that are
primarily of a regional focus, such as gastrointestinal, intraperitoneal, hepatic, ovarian
and thoracic. Upon completion of the activity, learners from several disciplines should
be able to discuss the latest regional therapies in surgical oncology.
Who Should Attend
This course is designed for physicians and nurses practicing in the areas of Medical,
Surgical, Thoracic and Gynecologic Oncology and Gastroenterology.
Continuing Education Credit
The University of Pittsburgh School of Medicine is accredited by the Accreditation Council
for Continuing Medical Education to provide continuing medical education for physicians.
The University of Pittsburgh School of Medicine designates this educational activity for
a maximum of 19.0 AMA PRA Category 1 Credits™. Each physician should claim only
credit commensurate with the extent of their participation in the activity.
Other health care professionals are awarded 1.90 continuing education units (CEU’s)
which are equal to 19.0 contact hours.
Special Needs
Participation by all individuals is encouraged. Advance notification of any special needs
will help us provide better service. Please notify us of your needs at least two weeks in
advance of the program by calling Maureen Hewko at (412) 623-5993.
Schedule – Saturday, February 15, 2014
6:45 am Registration and Breakfast
7:00 am Welcome
Moderators: Steven Ahrendt, MD and James Cusack, MD
7:15 am Peritoneal Surface Disease with Synchronous Hepatic Involvement
Treated with Cytoreductive Surgery (CRS) and Hyperthermic
Intraperitoneal Chemotherapy (HIPEC)
Andrea Doud, MD, et. al.
7:30 am Nomograms to Predict Prognosis in Pseudomyxoma Peritonei:
A PSOGI Multicenter Study
Shigeki Kusamura, MD, et. al.
7:45 am Extra-appendiceal Origin does not Affect Prognosis in Patients with
Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and HIPEC
Dario Baratti, MD, et. al.
8:00 am Evaluation of a New Staging Classification and a Peritoneal Surface
Disease Severity Score (PSDSS) in 210 Patients with Mucinous
Appendiceal Neoplasms
Jesus Esquivel, MD, et. al.
8:15 am GUEST LECTURER
Comprehensive Palliative Care for Peritoneal Carcinomatosis
Laura Lambert, MD
8:45 am Break with Refreshments/Exhibitors
Moderators: Fabian Johnston, MD and Amer Zureikat, MD
9:00 am Learning Curve and Outcomes of Cytoreductive Surgery and
HIPEC for Peritoneal Malignancies
Patricio Polanco, MD, et. al.
9:15 am HIPEC in Peritoneal Dominant Metastatic Colorectal Cancer
Robert Martin, MD, et. al.
The University of Pittsburgh, as an educational institution and as an employer, values equality of opportunity, human dignity, and
racial/ethnic and cultural diversity. Accordingly, as fully explained in Policy 07-01-03, the University prohibits and will not engage
in discrimination or harassment on the basis of race, color, religion, national origin, ancestry, sex, age, marital status, familial
status, sexual orientation, gender identity and expression, genetic information, disability, or status as a veteran. The University
also prohibits and will not engage in retaliation against any person who makes a claim of discrimination or harassment or who
provides information in such an investigation. Further, the University will continue to take affirmative steps to support and advance
these values consistent with the University’s mission. This policy applies to admissions, employment, and access to and treatment
in University programs and activities. This is a commitment made by the University and is in accordance with federal, state, and/
or local laws and regulations. For information on University equal opportunity and affirmative action programs, please contact:
University of Pittsburgh; Office of Affirmative Action, Diversity, and Inclusion; Carol W. Mohamed, Director (and Title IX, 504 and
ADA Coordinator); 412 Bellefield Hall; 315 South Bellefield Avenue; Pittsburgh, PA 15260; 412-648-7860. For complete details on
the University’s Nondiscrimination Policy, please refer to Policy 07-01-03. For information on how to file a complaint under this
policy, please refer to Procedure 07-01-03.
~ 4 ~ ~ 5 ~
9:30 am What is the Impact of Diaphragmatic Involvement During Cytoreductive
Surgery/HIPEC on Short Term Outcomes?
Bernardo Franssen, MD, et. al.
9:45 am DEBATE
HIPEC for Colorectal Cancer — Investigational vs.
Standard of Care
Garrett Nash, MD and Jesus Esquivel, MD
10:15 am Break Until Evening Session
4:00 pm Poster Viewing and Grading
Moderators: Marilyn Huang, MD and Marcello Deraco, MD
4:30 pm Comparison of MRI and CT for Predicting the Peritoneal Cancer Index
(PCI) Preoperatively in Patients Being Considered for Cytoreductive
Surgical Procedures
Russell Low, MD, et. al.
4:45 pm Association Between Hospital Finances, Payer Mix, and Complications
After HIPEC: Deficiencies in the Current Healthcare Reimbursement
System and Future Implications
Charles Staley, MD, et. al.
5:00 pm Maximal Cytoreduction and Hyperthermic Intraperitoneal
Chemotherapy in Advanced Ovarian Cancer
Paolo Sammartino, MD, et. al.
5:15 pm Intraperitoneal Chemotherapy and Ileostomies in Ovarian Cancer
Gleneara Bates, MD, et. al.
5:30 pm Obesity, Lymphadenectomy, and Survival Outcomes in Intermediate to
High-risk, Early Stage Endometrial Cancer Patients
Faina Linkov, MD, et. al.
5:45 pm Cytoreductive Surgery (CRS) and HIPEC in Patients with Recurrent
Platinum-Resistant Ovarian Carcinoma
C. Komen Brown, MD, et. al.
6:00 pm GUEST LECTURER
Is there a Role for HIPEC in Ovarian Cancer?
C. William Helm, MB.BChir
6:30 pm Light Dinner/Exhibitors
Moderators: Douglas Tyler, MD and Charlotte Ariyan, MD
6:45 pm Establishment of a National Guideline for the Use of Cytoreductive
Surgery and HIPEC in the Treatment of Peritoneal Surface
Malignancies in Austria
Thomas Bachleitner-Hofman, MD, et. al.
7:00 pm Accordion Severity Grading and Aggregate Postoperative
Morbidity Burden of CS-HIPEC in a Community Hospital
Jan Franko, MD, et. al.
7:15 pm Quality of Life After Isolated Limb Infusion for In-transit
Melanoma of the Extremity
Betty Jiang, MD, et. al.
7:30 pm Hyperthermic Isolated Limb Perfusion (ILP) with
Curaxins for Melanoma
Minhyung Kim, MD, et. al.
7:45 pm Isolated Limb Infusion is Feasible at Lower Volume
Regional Cancer Centers
David Jeffcoach, MD, et. al.
8:00 pm DEBATE
First Line Treatment for in Transit Melanoma —
Systemic vs. Regional
Steven O’Day, MD and John Kane III, MD
8:30 pm Evening Session Adjournment
8:45 pm Meet the Speakers Reception
~ 6 ~ ~ 7 ~
Sunday, February 16, 2014
6:45 am Registration and Breakfast
7:00 am Welcome
Moderators: T. Clark Gamblin, MD, MS and Martin Goodman, MD
7:15 am Neutrophil-lymphocyte Ratio: A Simple and Novel Biomarker
for Prediction of Survival After Radioembolization for Metastatic
Colorectal Cancer
Samer Tohme, MD, et. al.
7:30 am Transarterial Chemoembolization for Metastatic Neuroendocrine
Tumors: A Single Institution Review of 197 Patients
Lawrence Shirley, MD, et. al.
7:45 am Hepatic Artery Infusion for Recurrent or Chemoresistant Hepatic
Malignancy
Harold Wanebo, MD, et. al.
8:00 am Quality of Life Improvement and Enhanced Efficacy with Hepatic
Arterial Therapy of Doxorubicin-loaded beads (DEBDOX) in the
Treatment of Liver Metastases from Ocular Melanoma
Robert Martin, MD, et. al.
8:15 am GUEST LECTURER
Radioembolization and Chemoembolization 2014:
Current Status and Future Trends
William Rilling, MD
8:45 am Break with Refreshments/Exhibitors
Moderators: James Pingpank Jr., MD and Joel Baumgartner, MD
9:00 am Results and Feasibility of Sequential Isolated Hepatic Perfusion
and Percutaneous Hepatic Perfusion (PHP) With Melphalan for
Patients with Liver Metastases
Mei Li Kwong, MD, et. al.
9:15 am Radioembolization for Unresectable Colorectal Liver Metastases
Anthony Zacharias, MD, et. al.
9:30 am Post-TACE Neutrophil-to-Lymphocyte Ratio is Predictive of Survival in
Patients with Unresectable Neuroendocrine Liver Metastases
Neil Saunders, MD, et. al.
9:45 am DEBATE
High Grade, High PCI Carcinomatosis:
Is There a Role for CRS and HIPEC?
John Stewart, MD (Yes) and Kiran Turaga, MD (No)
10:15 am Break Until Evening Session
4:00 pm Poster Viewing and Grading
Moderators: C. Komen Brown, MD and Daniel Labow, MD
4:30 pm Outcomes Following Cytoreductive Surgery and HIPEC in 44 Patients
with Peritoneal Mesothelioma
Oliver Shihab, MD, et. al.
4:45 pm Iterative Cytoreductive Surgery and HIPEC for Recurrent Diffuse
Malignant Peritoneal Mesothelioma: Clinicopathologic Characteristics
and Survival Outcome
Chukwuemeka Ihemelandu, MD, et. al.
5:00 pm Cytoreductive Surgery with HIPEC for Signet Ring Peritoneal
Malignancies
Sarah McPartland, MD, et. al.
5:15 pm Cytoreductive Surgery and HIPEC in Children and Adolescents:
the First 50 Cases
Andrea Hayes-Jordan, MD, et. al.
5:30 pm Peritoneal Dominant Metastatic Colorectal Cancer
Robert Martin, MD, et. al.
5:45 pm Conversion Gastrectomy after Intravenous Intraperitoneal Paclitaxel
(PTX) Administration with Oral S-1 for Peritoneal Dissemination of
Advanced Gastric Cancer with Malignant Ascites
Joji Kitayama, MD, et. al.
~ 8 ~ ~ 9 ~
6:00 pm GUEST LECTURER
Pathologic Classification of PMP — Results of Basingstoke
Consensus Conference
Norman Carr, MD
6:30 pm Light Dinner/Exhibitors
Moderators: Nathan Bahary, MD, PhD and Richard Royal, MD
6:45 pm Neoadjuvant Laparoscopic HIPEC for Peritoneal Metastases from
Gastric Cancer
Yutaka Yonemura, MD, et. al.
7:00 pm Cytoreductive Surgery with HIPEC — an Emerging Treatment Option
for Advanced Goblet Cell Tumors of the Appendix
Yarrow McConnell, MD, et. al.
7:15 pm Heated Intraperitoneal Gemcitabine for Resectable Pancreatic
Carcinoma: Morbidity and Early Survival Data from Two Centers
Lana Bijelic, MD, et. al.
7:30 pm Management of Peritoneal Carcinomatosis in Columbia:
Developing a National Center for Excellence
Fernando Arias, MD, et. al.
7:45 pm Intraperitoneal Chemotherapy is Not Associated with Increased 30-Day
Operative Morbidity and Mortality: A Matched Study of Colorectal
Cancer Patients with and without Intraperitoneal Chemotherapy
Edmund Bartlett, MD, et. al.
8:00 pm GUEST LECTURER
Video Demonstration of Five Parietal Peritonectomy Procedures Used
for Cytoreductive Surgery of Peritoneal Metastases
Paul Sugarbaker, MD, FACS, FRCS
8:30 pm American Society of Peritoneal Surface Malignancies
Fourth Annual Meeting
9:30 pm Evening Session Adjournment
Monday, February 17, 2014
6:45 am Registration and Breakfast
Moderators: Jason Foster, MD and Timothy Kennedy, MD
7:00 am Impact of Distal Pancreatectomy on Outcomes of Peritoneal Surface
Disease Treated with Cytoreductive Surgery and HIPEC
Andrea Doud, MD, et. al.
7:15 am Morbidity of Abdominal Wall Resections (AWR) and Reconstructions
During Cytoreductive Surgery and HIPEC
Maria Nunez, MD, et. al.
7:30 am Role of Obesity in the Proliferation and Metastasis of Endometrial and
Ovarian Adenocarcinoma
Faina Linkov, MD, et. al.
7:45 am Immunohistochemical Evaluation of Calretinin, Claudin, WT-1,
Podoplanin, CK 5/6, Topoisomerase IIa, MCM7, ER, and PGR in Diffuse
Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray
Marcello Deraco, MD, et. al.
8:00 am GUEST LECTURER
Pre-Clinical Research for Appendiceal Cancer:
Where We’ve Been and Where We Need to Go
Haroon Choudry, MD
8:45 am Break and Exhibitors
Moderators: Brian Loggie, MD and Herbert Zeh III, MD
9:00 am Histologic Changes Associated with HIPEC
Patrick Wagner, MD, et. al.
9:15 am Next Generation Sequencing Reveals Significant Genomic Heterogeneity
in Appendiceal Neoplasms
Laura Lambert, MD, et. al.
9:30 am Oncolytic Vaccinia Virus and Irinotecan Synergize to Improve Treatment
of Colorectal Carcinomatosis
J. Andrea McCart, MD, et. al.
~ 10 ~ ~ 11 ~
9:45 am A New Micronutrient Formulation with Hyperthermic Mitomycin C
Enhances Colorectal Tumor Cell Killing in Vitro
Daniel Cucher, MD, et. al.
10:00 am The Effects of Hyperthermia on Cytotoxicity of Intracavitary
Chemotherapeutic Drugs
Gleneara Bates, MD, et. al.
10:15 am CASE PRESENTATIONS/PANEL DISCUSSION
Case Discussants: H. Richard Alexander, MD, and Edgar Guillermo Flores-Ayala, MD
Cardiac Toxicity Associated with Intraperitoneal Administration
of Mitomycin C
Sarah McPartland, MD, et. al.
Cytoreductive Surgery (CRS) and HIPEC in a Patient with Previous
Kidney/Pancreas Transplant
Charles Staley, MD, et. al.
Rare Presentation of Primary Papillary Serous Carcinoma (PSCP)
in a Male Patient
Charles Staley, MD, et. al.
Cytoreductive Surgery and HIPEC for Desmoplastic Small
Round Cell Tumor
Jason Denbo, MD, et. al.
Combined Systemic and Regional Therapy in a Young Adult with
Peritoneal Carcinomatosis from Small Bowel Adenocarcinoma
Teresa Kim, MD, et. al.
Use of a Treatment Efficacy Score in Predicting Patients at Risk for
Extensive Early Recurrence after CRS and HIPEC for Peritoneal
Carcinomatosis Arising from the Appendix
Nelson Royall, MD, et. al.
11:45 am Announcement and Poster Presentation of Poster Award Winners
11:50 am Conference Adjournment
Poster Presentations
1. Hospital Factors that Contribute to Inpatient Mortality in Patients with Peritoneal Carcinomatosis: Larger Hospitals are Not Better. Evan Glazer, MD, et. al.
2. Old Versus Too Old for Surgery in Patients with Peritoneal Carcinomatosis. Evan Glazer, MD, et. al.
3. Neoadjuvant Pelvic Perfusion May Facilitate Resection of Pelvic Recurrent Rectal Cancer. Harold Wanebo, MD, et. al.
4. Escalation of Socioeconomic Disparities Among Patients with Colorectal Cancer Receiving Advanced Surgical Treatment. Parissa Tabrizian, MD, et. al.
5. Laparoscopic Evacuation of Mucinous Ascites for Palliation in Unresectable Pseudomyxoma Peritonei. Kaitlyn Kelly, MD, et. al.
6. Pancreatic Fistulae in Patients Undergoing Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) and Distal Pancreatectomy are more Severe than those Undergoing Distal Pancreatectomy Alone. Stephanie Downs-Canner, MD, et. al.
7. Predictors of Progression in Patients with High-Grade Appendiceal or Colorectal Adenocarcinoma After Cytoreductive Surgery and HIPEC. Joel Baumgartner, MD, et. al.
8. Validation of the Peritoneal Surface Disease Severity Score in Patients with Sarcomatosis Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. George Salti, MD, et. al.
9. The Role of E2F1 in Well-Differentiated Papillary Mesothelioma of the Peritoneum (WDPMP). Gleneara Bates, MD, et. al.
10. Neutrophil-to-lymphocyte Ratio as a Predictor of Survival in Patients with Advanced Hepatocellular Carcinoma Receiving Yttrium-90 Radioembolization. Daniel Sukato, MD, et. al.
11. Central Sarcopenia Does not Predict Occurrence of Clinically Dominant Acute Complication after Cytoreductive Abdominal Surgery in a Community Cancer Center. Shawna Grimm, MD, et. al.
12. Preoperative Ureteral Stenting for Patients Undergoing Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy. Carlos HF Chan, MD, et. al.
13. Current Trends in the Management of Malignant Peritoneal Mesothelioma. John Miura, MD, et. al.
14. Optimizing the Role of the Advanced Practice Provider in a HIPEC program. Deborah Schneider, et. al.
15. Development of a Cytoreductive Surgery and HIPEC Program: The Montefiore Einstein Experience. Oscar Serrano, MD, et. al.
16. Cytoreductive Surgery and HIPEC for Appendiceal Neoplasm: Delay to Treatment without Significant Consequence? Julie Alosi, MD, et. al.
~ 12 ~ ~ 13 ~
17. Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: A Systematic Review. Joseph Helm, MD, et. al.
18. Role of Laparoscopy in Patients with Peritoneal Metastases Considered for Cytoreductive Surgery and HIPEC. Thejus Jayakrishnan, MD, et. al.
19. Role of Falciform Ligament and Ligamentum Teres Hepatis Resection in HIPEC. Thejus Jayakrishnan, MD, et. al.
20. Surgical Treatment for Mucinous Appendiceal Patients — The Role of Ostomies in Cytoreductive Surgery. Melanie Ongchin, MD, et. al.
21. Elevation of Alkaline Phosphatase Prior to Transarterial Chemoembolization for Metastatic Neuroendocrine Tumors Predicts a Worse Outcome. Jill Onesti, MD, et. al.
22. Outcomes of Cytoreductive Surgery and HIPEC in Patients with High Grade-High Volume Disseminated Mucinous Appendiceal Neoplasms. Patricio Polanco, MD, et. al.
23. Outcomes of HIPEC Therapy at Low Volume Center. David Lee, MD, et. al.
24. Perioperative Clinical Factors May Predict Ineffectiveness of a Sole Epidural Based Pain Management Regimen for Patients Undergoing Cytoreductive Surgery with HIPEC. Jose Soliz, MD, et. al.
25. Peritoneal Mesothelioma in Mexico? Edgar Guillermo Flores-Ayala, MD, et. al.
26. Peritoneal Carcinomatosis from Lung Cancer: Is Debulking Surgery a Suitable Option in Selected Patients. Simone Sibio, MD, et. al.
27. Sentinel Node Biopsy Under Local Anesthesia: The European Institute of Oncology Experience. Alessandro Testori, MD, et. al.
28. Another Unusual Application of Cytoreductive Surgery and Hyperthermic Perioperative Chemotherapy to Definitely Treat a Rare Disease. Paul Sugarbaker, MD, et. al.
29. Prognostic Significance of Clinicopathological Parameters in Diffuse Malignant Peritoneal Mesothelioma. Sandy Liu, MD, et. al.
30. Immunotherapeutic Intra-arterial Adoptive Transfer In a Murine Model. Asher Blum, MD, et. al.
31. A Systematic Review and Meta-Analyses of Hepatic Artery Based Therapies for Unresectable Intrahepatic Cholangiocarcinoma. Lucas Boehm, MD, et. al.
32. Modified Vesicular Stomatitis Virus as Treatment of Peritoneal Surface Dissemination of Colorectal Cancer. Michelle L. Bryan, MD, et. al.
33. Concomitant Plural and Peritoneal Malignant Mesotheliomas: A single Institution Experience of 10 Cases. Jennifer Collins, MD, et. al.
34. Failure to Rescue in the Surgical Oncology Population. Katherine Kiolbasa, MD, et. al.
35. Survival, Morbidity and Peritoneal Carcinomatosis Index. Horacio Lopez-Basave, MD, et. al.
Course Co-Directors
H. Richard Alexander, MD
Professor of Surgery
University of Maryland School of Medicine
Baltimore, MD
David L. Bartlett, MD
Professor of Surgery
University of Pittsburgh School of Medicine
Robert P. Edwards, MD
Professor, Obstetrics, Gynecology and
Reproductive Sciences
University of Pittsburgh School of Medicine
T. Clark Gamblin, MD, MS
Stuart D. Wilson Chair in Surgical Oncology
Chief, Division of Surgical Oncology
Associate Professor of Surgery
Medical College of Wisconsin
Milwaukee, WI
Invited Faculty
Steven Ahrendt, MD
Associate Professor of Surgery
University of Pittsburgh School of Medicine
Charlotte Ariyan, MD
Associate Professor of Surgery
Memorial Sloan-Kettering Cancer Center
New York, NY
Nathan Bahary, MD, PhD
Associate Professor of Medicine
Division of Medicine and Oncology
University of Pittsburgh School of Medicine
Joel Baumgartner, MD
University of California San Diego
La Jolla, CA
C. Komen Brown, MD
Cancer Treatment Centers of America
Zion, IL
Norman Carr, MD
Faculty of Medicine,
University Hospital of Southampton
Southampton, UK
Haroon Choudry, MD
Assistant Professor of Surgery
University of Pittsburgh School of Medicine
James C. Cusack, MD
Associate Professor of Surgery
Harvard Medical School
Massachusetts General Hospital
Boston, MA
Marcello Deraco, MD
Surgical Oncologist
Fondazione IRCCS Instituto
Nazionale dei Tumori
Milano, Italy
Jesus Esquivel, MD
Medical Director, International
Oncology Initiatives
Cancer Treatment Centers of America
Philadelphia, PA
Jason Foster, MD
Assistant Professor of Surgery
University of Nebraska
Omaha, NE
Martin Goodman, MD
Assistant Professor of Surgery
Tufts Medical Center
Boston, MA
C. William Helm, MB.BChir
Consultant Gynaecological Oncologist,
Northern Gynaecological Oncology Centre,
Queen Elizabeth Hospital,
United Kingdom
Marilyn Huang, MD
Assistant Professor
University of Pittsburgh School of Medicine
~ 14 ~ ~ 15 ~
Fabian Johnston, MD
Assistant Professor of Surgery
Medical College of Wisconsin
Milwaukee, WI
John M. Kane III, MD
Associate Professor of Oncology
Roswell Park Cancer Institute
Associate Professor of Surgery
University at Buffalo
Buffalo, NY
Timothy Kennedy, MD
Assistant Professor of Surgery
Montefiore Medical Center
New York, NY
Daniel Labow, MD
Associate Professor
Mt. Sinai School of Medicine
New York, NY
Laura Lambert, MD
University of Massachusetts
Memorial Medical Center
Worcester, MA
Brian Loggie, MD
Associate Professor of Surgery
University of Nebraska
Omaha, NE
Garrett Nash, MD
Associate Professor of Surgery
Memorial Sloan Kettering Cancer Center
New York, NY
Steven J. O’Day, MD
Beverly Hills Cancer Center
Department of Medical Oncology
Los Angeles, CA
James Pingpank Jr., MD
Associate Professor of Surgery
University of Pittsburgh School of Medicine
William Rilling, MD
Associate Professor of Surgery
Medical College of Wisconsin
Milwaukee, WI
Richard Royal, MD
Associate Professor
MD Anderson Cancer Center
Houston, TX
John H. Stewart, MD
Associate Professor of Surgery
Wake Forest University
Winston-Salem, NC
Paul H. Sugarbaker, MD
Director, Program in Peritoneal
Surface Malignancy
Washington Hospital Centre
Washington, DC
Kiran Turaga, MD
Assistant Professor of Surgery
Medical College of Wisconsin
Milwaukee, WI
Douglas S. Tyler, MD
Professor of Surgery
Duke University
Durham, NC
Herbert J. Zeh III, MD
Associate Professor of Surgery
University of Pittsburgh School of Medicine
Amer Zureikat, MD
Assistant Professor of Surgery
University of Pittsburgh School of Medicine
Faculty for this activity has been required to
disclose all relationships with any proprietary
entity producing health care goods or services.
Faculty reside in the Pittsburgh, Pennsylvania,
metropolitan area unless indicated otherwise.
Abstract/Poster Presenters
Julie Alosi, MD
Roswell Park Cancer Institute
Buffalo, NY
Fernando Arias, MD
Hospital Universitario Fundacion
Santa Fe de Bogota
Bogota, Colombia
Thomas Bachleitner-Hoffman, MD
Medical University of Vienna
Vienna, Austria
Dario Baratti, MD
Milan Tumor Institute
Milan, Italy
Edmund Bartlett, MD
Hospital of the University of Pennsylvania
Philadelphia, PA
Gleneara Bates, MD
Columbia University Medical Center
New York, NY
Lana Bijelic, MD
Washington Hospital Center
Washington, DC
Asher Blum, MD
Roswell Park Cancer Institute
Buffalo, NY
Lucas Boehm, MD
Medical College of Wisconsin
Milwaukee, WI
Michelle L. Bryan, MD
Wake Forest Baptist Health
Winston-Salem, NC
Carlos HF Chan, MD
Massachusetts General Hospital
Boston, MA
Jennifer Collins, MD
University of Maryland Medical Center
Baltimore, MD
Daniel Cucher, MD
University of Arizona
Tucson, AZ
Jason Denbo, MD
University of Tennessee Health
Sciences Center
Memphis, TN
Andrea Doud, MD
Wake Forest Baptist Health
Winston-Salem, NC
Stephanie Downs-Canner, MD
UPMC Shadyside
Pittsburgh, PA
Edgar Guillermo Flores-Ayala, MD
Hospital Regional de Alta Especilidad
de Oaxaca
Oaxaca, Oaxaca, Mexico
Jan Franko, MD
Mercy Medical Center
Des Moines, IA
Bernardo Franssen, MD
Mount Sinai School of Medicine
New York, NY
Evan Glazer, MD
The University of Arizona
Tucson, AZ
Shawna Grimm, MD
Mercy Medical Center
Des Moines, IA
Andrea Hayes-Jordan, MD
Assistant Professor of Pediatric Surgery
University of Houston MD Anderson
Cancer Center
Houston, TX
~ 16 ~ ~ 17 ~
Joseph Helm, MD
Medical College of Wisconsin
Milwaukee, WI
Chukwuemeka Ihemelandu, MD
Medstar Washington Hospital Center
Washington, DC
Thejus Jayakrishnan, MD
Medical College of Wisconsin
Milwaukee, WI
David Jeffcoach, MD
University of Tennessee Medical Center
Knoxville, TN
Betty Jiang, MD
Duke University Medical Center
Durham, NC
Kaitlyn Kelly, MD
University of California San Diego
La Jolla, CA
Minhyung Kim, MD
Roswell Park Cancer Institute
Buffalo, NY
Teresa Kim, MD
Massachusetts General Hospital
Boston, MA
Katherine Kiolbasa, MD
Froedtert Hospital
Milwaukee, WI
Joji Kitayama, MD
University of Tokyo
Tokyo, Japan
Shigeki Kusamura, MD
Istituto Nazionale Tumori di Milano
Milano, Italy
Mei Li Kwong, MD
National Cancer Institute, NIH
Bethesda, MD
David Lee, MD
St. Luke’s Roosevelt Hospital
New York, NY
Faina Linkov, MD
University of Pittsburgh
Pittsburgh, PA
Sandy Liu, MD
University of Maryland Medical Center
Baltimore, MD
Horacio Lopez-Basave, MD
Instituto Nacionale de Cancerologia
de Mexico
Distrito Federal, Mexico
Russell Low, MD
Sharp Memorial Hospital
San Diego, CA
Robert Martin, MD
University of Louisville
Louisville, KY
J. Andrea McCart, MD
Toronto General Research Institute
Toronto, Ontario, Canada
Yarrow McConnell, MD
University of Calgary
Calgary, Alberta, Canada
Sarah McPartland, MD
Tufts Medical Center
Boston, MA
John Miura, MD
Medical College of Wisconsin
Milwaukee, WI
Maria Nunez, MD
Mercy Medical Center
Baltimore, MD
Jill Onesti, MD
The Ohio State University
Columbus, OH
Melanie Ongchin, MD
University of Pittsburgh
Pittsburgh, PA
Patricio Polanco, MD
University of Pittsburgh
Pittsburgh, PA
Nelson Royall, MD
MD Anderson Cancer Center Orlando
Orlando, FL
George Salti, MD
The University of Illinois at Chicago
Chicago, IL
Paolo Sammartino, MD
University of Rome
Rome, Italy
Neil Saunders, MD
The Ohio State University
Columbus, OH
Deborah Schneider
Medical College of Wisconsin
Milwaukee, WI
Oscar Serrano, MD
Montefiore-Einstein Center for Cancer Care
Bronx, NY
Oliver Shihab, MD
North Hampshire Hospital
Basingstoke, UK
Lawrence Shirley, MD
Ohio State University
Columbus, OH
Simone Sibio, MD
University Sapienza of Rome
Rome, Italy
Jose Soliz, MD
MD Anderson Cancer Center
Houston, TX
Charles Staley, MD
Emory University
Atlanta, GA
Daniel Sukato, MD
University of Pittsburgh
Pittsburgh, PA
Parissa Tabrizian, MD
Mount Sinai Medical Center
New York, NY
Alessandro Testori, MD
European Institute of Oncology
Milan, IT
Samer Tohme, MD
University of Pittsburgh
Pittsburgh, PA
Patrick Wagner, MD
Winchester Medical Center
Winchester, VA
Harold Wanebo, MD
Landmark Medical Center
Woonsocket, RI
Yutaka Yonemura, MD
Haruki-Moto-Machi
Kishiwada, Osaka, Japan
Anthony Zacharias, MD
Medical College of Wisconsin
Milwaukee, WI
~ 18 ~ ~ 19 ~
Registration Information
Online Registration is accepted until February 14, 2014. After this date, you are only
able to register for the conference on site.
Registering online is the quickest and easiest way to reserve your space at CCEHS
conferences.
Visit our online registration site at https://ccehs.upmc.com. Scroll down to the Ninth
International Symposium on Regional Cancer Therapies section on the web page.
• Click the registration button and enter all of the requested information.
• After registering, an electronic confirmation will be sent to the email address you
provided when you registered.
Registration is not complete until you receive the confirmation email for your
preregistration. If you do not receive this letter within 5-7 days of registration, please
contact Maureen Hewko at (412) 623-5993.
You must bring this confirmation with you to the conference.
Registration Cancellation
All cancellations must be in writing and sent to us via US mail, email or fax. Tuition
cancellations postmarked or date stamped before January 15, 2014 will be completely
refunded. After January 15, 2014, a $35 administrative fee will be assessed. No refunds
will be made after February 1, 2014.
Conference contact for cancellation requests:
Maureen Hewko, MBA
UPMC Cancer Pavilion 413, 5150 Centre Avenue
Pittsburgh, PA 15232
Email: [email protected] • Telephone: (412) 623-5993
Fax: (412) 692-2520
Registration Fees
$300 Physicians and researchers
$200 Nurses and other health care professionals
Registration fee includes:
• Continuing education credit
• Registration and course materials
• Continental breakfast, refreshments and a light dinner
Meeting Location
The conference will be held at the Sheraton Steamboat
Springs, 2220 Village Inn Court, PO Box 774808.
Conference reservations are at the sole responsibility
of the attendees who may contact the hotel.
If registering for a room at the hotel online, please go to https://www.starwoodmeeting.
com/StarGroupsWeb/booking/reservation?id=1308271577&key=5F82A
If you wish to make your reservation by phone, please call John at 970-871-6550 and
ask for the UPP room block.
Accommodations
Nightly Guest Room Rates: $289 per night
Note: Resorts room rates are subject to additional taxes and resort fees as applicable.
Transportation
For up-to-date transportation information, go to the Koch Center Website:
http://www.regionaltherapies.com
For additional information, contact:
Maureen Hewko, MBA
Telephone: (412) 623-5993
Fax: (412) 692-2520
Email: [email protected]
Koch Center Website: http://www.regionaltherapies.com
Visit the Center for Continuing Education
in the Health Sciences Web Site
Our Internet address is: https://ccehs.upmc.com
The UPMC Center for Continuing Education in the Health Sciences invites you to visit
our web location. Receive information on CME programs, earn CME credits on the
Internet, and access information about our formal courses and much more. Discover
who we are and how you can contact us. Please visit our web location often to get
updated information on upcoming programs.